secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001213900-23-040004
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada provides Phase 3 update for REL-1017 in MDD; cash $132.4M
-----------------------------------------------------------------

- Cash and equivalents $132.4M as of 3/31/23; ~30.1M common shares outstanding (45.6M as-converted).
- Reliance I and III did not meet primary endpoints; post-hoc analysis with removal of two sites showed -4.1 MADRS difference (p=0.02).
- Key trial improvements: require medical records to verify depression, limit patients per site, simplify assessments.
- Upcoming milestones: complete Reliance II (adjunctive) in 1H 2024; initiate additional Phase 3 adjunctive trial mid-2023, completion 2H 2024.
- No serious treatment-related TEAEs, no abuse potential; safety profile consistent across studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023040004/0001213900-23-040004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023040004/ea178627-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-040004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer